<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52061">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047630</url>
  </required_header>
  <id_info>
    <org_study_id>C13-11-1242</org_study_id>
    <nct_id>NCT02047630</nct_id>
  </id_info>
  <brief_title>Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare efficacy and tolerability of the
      brand-name latanoprost and one of its generic version in subjects with primary open angle
      glaucoma or ocular hypertension.

      This randomized, double-blinded, cross-over design study has a 4 months follow-up. There are
      two periods of 8 weeks. During the first period, subjects put brand-name latanoprost in one
      eye and the generic version in the other one. In the second period, drops are switched from
      one eye to the other. There are intraocular pressure measurements (diurnal curves) on day 0
      (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of
      second period). Variations of intraocular pressure in each eye will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Intraocular Pressure (IOP)</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Goldman applanation tonometry will be used to measure IOP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Conjunctival hyperemia</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal staining</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Oxford grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSS-IOP (Treatment Satisfaction Survey for IntraOcular Pressure)</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Generic latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 eye drop hs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 eye drop hs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic latanoprost</intervention_name>
    <arm_group_label>Generic latanoprost</arm_group_label>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brand-name latanoprost</intervention_name>
    <arm_group_label>Generic latanoprost</arm_group_label>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years old

          2. Primary open angle glaucoma, glaucoma suspect or ocular hypertension

          3. Bilateral

          4. Without any treatment or treated with latanoprost or another prostaglandin analog

          5. Intraocular pressure &gt;21mmHg (without treatment or after a washout period)

        Exclusion Criteria:

          1. Intraocular pressure &gt;30mmHg

          2. Secondary glaucoma (uveitic, neovascular, traumatic ) or congenital glaucoma

          3. Pseudoexfoliation syndrome

          4. Pigmentary dispersion syndrome or Pigmentary glaucoma

          5. Severe glaucoma; Cup-to-disc ratio ≥9/10 OU Loss of central visual field (central
             10°)

          6. Use of other topical medication to lower intraocular pressure

          7. Pregnancy and breast-feeding

          8. Being allergic to latanoprost or benzalkonium chloride (BAK)

          9. Current use of acetazolamide (Diamox)

         10. Changes of systemic doses of beta-blockers during study

         11. Recent use of topical corticosteroids (&lt;1 month)

         12. Contact lens wearer

         13. Closed angle at gonioscopy or past angle closure glaucoma

         14. Filtration surgery (example. : trabeculectomy)

         15. Selective Laser Trabeculoplasty (SLT) or Argon Laser Trabeculoplasty(ALT)

         16. Recent Intraocular surgery (&lt;3 months)

         17. Refractive surgery

         18. Recent iridotomy or capsulotomy (&lt;3 months)

         19. Past medical history of ocular trauma (example : angle recession)

         20. Past or active uveitis

         21. Herpetic keratitis

         22. Monocular vision
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Josée Fredette, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec; Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Josée Fredette, MD, FRCSC</last_name>
    <phone>418-682-7511</phone>
    <phone_ext>4846</phone_ext>
    <email>marie-josee.fredette.cha@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu Mercier, MD</last_name>
    <email>mathieu.mercier.4@ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Josée Fredette, MD, FRCSC</last_name>
      <phone>418-682-7511</phone>
      <phone_ext>4846</phone_ext>
      <email>marie-josee.fredette.cha@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marcelle Giasson, BSc</last_name>
      <phone>418-682-7511</phone>
      <phone_ext>4854</phone_ext>
      <email>marcelle.giasson@fmed.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Josée Fredette, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Québec, CHU de Québec</investigator_affiliation>
    <investigator_full_name>Marie-Josée Fredette</investigator_full_name>
    <investigator_title>MD, FRCSC</investigator_title>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>latanoprost</keyword>
  <keyword>generic</keyword>
  <keyword>intraocular pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
